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Abstract
Carbohydrate response element binding protein (ChREBP) is a glucose-sensing transcription factor that mediates the induction of
glycolytic and lipogenic genes in response to glucose. We investigated the expression patterns of ChREBP and glucose transporters
(GLUTs) in human hepatocellular carcinoma (HCC) and their association with HCC progression. ChREBP, GLUT2 and GLUT1
immunohistochemistry were performed on liver tissue array containing normal liver tissue, HCC adjacent tissue and cancer tissue of
different HCC stages. The effect of HCC malignancy on protein expression was analyzed with one-way ANOVA. The correlations
between protein expressions were analyzed with Pearson Correlation test. We found that ChREBP protein expression tended to be
positively correlated to liver malignancy. GLUT2 protein expressionwas significantly reduced in humanHCC as compared to normal
liver tissue and its expression in HCC was inversely associated to malignancy (p < 0.001). In contrast, GLUT1 was significantly
increased in cancer cells and its expression was positively correlated to malignancy (p < 0.001). Furthermore, GLUT1 expression was
positively associated to ChREBP expression (r = 0.481, p < 0.0001, n = 70) but negatively correlated to GLUT2 expression (r =
−0.320, p = 0.007, n = 70). Notably, ChREBP-expressing hepatocytes did not express GLUT2 but GLUT1. This is the first report
unveiling expressions of ChREBP andGLUT2/GLUT1 and their relations in HCC. The expression patterns are related tomalignancy
and this information would facilitate evaluation of clinical behavior and treatment of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer in men and the seventh in women. Many HCC patients
have progressed to advanced stages at time of diagnosis,
resulting in poor prognoses and high mortality. Despite vari-
ous treatment options, survival of HCC is poor due to late
diagnosis and resistance to chemotherapy. The current gold
standard and most commonly used diagnostic marker for
HCC is plasmic alpha-fetoprotein (AFP) along with ultra-
sound every 6 to 12 months, but this is far from satisfactory.
Only serum AFP levels of more than 400 ng/mL are consid-
ered truly diagnostic, but such high values are observed only
in a small percentage of patients with HCC at advanced stages
[1]. Although many molecules have been considered to asso-
ciate with diagnosis and prognosis, their presumed merits are
controversial [2, 3]. Accordingly, new diagnostic and prog-
nostic factors are needed to improve HCC diagnosis and
treatment.
Evidence is accumulating that perturbed cellular metabo-
lism predisposes human to tumor development. Metabolic
diseases such as obesity and diabetes are associated with in-
creased risk to develop various cancers [4–6]. In addition,
many human tumors display a high rate of aerobic glycolysis,
de novo fatty acid synthesis and nucleotide biosynthesis [7, 8].
It has been proposed that increased glucose metabolism
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promotes lipogenesis and nucleotide biosynthesis, and en-
hances tumor cell growth and proliferation by providing es-
sential synthetic and bioenergetic molecules [9, 10].
Cancer cells acquire energy from glucose to satisfy their
high metabolic demands. Glucose and related hexoses are
transported into cells via glucose transporter (GLUT) family
proteins (Solute carrier, SLC2A family) [11]. To date, 14
GLUT family members have been identified, each of them
with different affinities for glucose and their expression pat-
terns are tissue dependent [12, 13]. Many studies have dem-
onstrated that the expression of glucose transporters, especial-
ly GLUT1, is increased in a variety of tumors, including pan-
creatic, breast, esophageal, and brain cancers [14, 15]. GLUT1
overexpression is associated with tumor progression and poor
overall survival in various malignant tumors [16, 17]. GLUT2
is expressed in liver, pancreatic islet cells and retina and it is
the most abundant glucose transporter in liver [18]. GLUT2
mRNA expression was shown to be increased in gastric tu-
mors [19] but decreased in insulinomas when compared to
normal tissues [20]. However, data on these glucose transport-
er expression in different stages of HCC have been lacking.
One of the master regulators of intracellular glucose me-
tabolism is carbohydrate responsive element binding protein
(ChREBP), a basic helix–loop–helix leucine zipper (bHLH-
LZ) transcription factor expressed in liver, white and brown
adipose tissues, intestine, muscle, and pancreatic β-cells [21,
22]. Elevated insulin, in response to increased glucose levels,
promotes ChREBP dephosphorylation and its translocation
from the cytoplasm to the nucleus where, in association with
its binding partner MLX (Max-like interacting protein), it
binds to carbohydrate response elements, present in the pro-
moters of target genes. Glucose metabolites F6P and acetyl-
CoA can increase ChREBP activity via O-linked glycosyla-
tion and acetylation, respectively [23–25]. The ChREBP/Mlx
heterodimer controls glucose and lipid metabolism through
regulating glycolytic (Pklr, Fk, Glut2, Glut4), gluconeogenic
(G6pc), and lipogenic (Fasn, Acc1, Scd1, Elovl6) gene expres-
sions [22, 26, 27], suggesting that ChREBP may have an
important role in the pathogenesis of metabolic diseases and
cancer. So far, most of the work on ChREBP has focused on
its function as a hepatic transcription factor, its activation by
glucose metabolites and its role in the regulation of lipogene-
sis. Little is known about the role of ChREBP in cancer cells.
Genomic analysis of ChREBP target gene expression in hu-
man hepatocellular carcinoma cell line HEPG2 by ChIP-
sequencing showed that ChREBP regulates genes associated
with a tumor metabolic phenotype and malignant progression,
such as tumor differentiation and motility [28]. Suppression of
ChREBP in hepatocellular carcinoma and colorectal cancer
cells led to reduced lipogenesis and nucleotide synthesis and
decreased proliferative and tumorigenic potential in mice [29].
In breast cancer, the level of ChREBP protein expression is
positively correlated with tumor progression [30]. However,
hepatic ChREBP expression has not been examined in human
HCC and the relationship between ChREBP expression and
the degree of liver tumor malignancy has yet to be
investigated.
In this study, we analyzed GLUT family members GLUT2
and GLUT1, and ChREBP protein expression levels in human
liver tissue array composed of normal, HCC and adjacent liver
tissue. We found that the expression of ChREBP showed a
tendency to increase with liver malignancy, but unexpectedly,
that GLUT2 protein expression was decreased in cancer cells
compared to normal hepatocytes and its expression was neg-
atively associated with advanced stages of HCC. GLUT1 was
increased in cancer tissues and its expression was significantly
correlated with clinical stage. Moreover, ChREBP and
GLUT1 expressions were positively correlated to each other
but GLUT1 and GLUT2 expressions were negatively corre-
lated. Therefore, a combined evaluation of ChREBP, GLUT1
and GLUT2 protein expression profile may provide a new
diagnostic and prognostic marker for HCC, that might be use-
ful in improving patient treatment and survival.
Materials and Methods
Human hepatic carcinoma and normal tissue microarray was
purchased from AURAGENE (TC0145, Changsha, China).
The tissue array contains 40 cases of hepatocellular carcino-
ma, 17 cases of normal tissue and 13 cases of adjacent normal
tissue. In addition, 5 pairs of cancer and adjacent normal tis-
sues were collected from the Second Affiliated Hospital of
Shantou University Medical College, Shantou, China. This
study has been approved by Shantou University medical col-
lege Ethic Committee. All methods were performed in accor-
dance with the relevant guidelines and regulations. Informed
consent was obtained from all participants and/or their legal
guardians.
Immunohistochemistry
Immunohistochemistry was carried out following an
established protocol [31]. Briefly, liver tissue microarray or
paraffin tissue sections were dewaxed, rehydrated through
graded ethanol and incubated with 3% hydrogen peroxide
for 30 min. Antigen retrieval was performed by heating the
sections to 95 °C in 0.01 mol/l citrate buffer (pH 6.0) for
15 min. Slides were then washed in PBS for 15 min and
treated with 10% normal horse serum for 30 min and incubat-
ed with primary antibody at 4 °C overnight. The reaction
products were detected with 3-amino-9-ethylcarbozole
(AEC) substrate-chromogen kit after incubating with the sec-
ondary antibody of Dako REAL EnVision Detection Kit
(Dako, Carpinteria, CA) for 30 min and washing in 0.1 M
PBS at room temperature. Staining with AEC resulted in red
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signals. The primary antibody for GLUT2 (Novus
Biologicals, NBP2-22218SS, USA), GLUT1 (Abcam,
ab115730, USA), were used at a 1:500 dilution and anti-
ChREBP (Novus Biologicals, NB400–135, USA) was used
at a 1:200 dilution. The antibodies against GLUT2 and
ChREBP were rabbit-derived polyclonal and the antibody
against GLUT1 was rabbit-derived monoclonal. For negative
controls, the primary antibodies were replaced with PBS.
Stain-Decolorize-Stain (SDS) Method for Liver
Microarray
The stain-decolorize-stain method was performed to show
whether GLUT2 and ChREBP are expressed in the same
hepatocytes/pattern according to an established procedure
[32]. Briefly, immunohistochemistry of ChREBP was first
performed on the liver microarray. After visualization and
taking photos, the slides were decolorized with 80% alcohol
for half an hour at room temperature and then heated in a
microwave oven for 10 min to remove the bound antibodies.
The microarray and slides were then incubated with GLUT2
antibody at 4 °C overnight. After visualization with the AEC
kit, photos were taken at the same fields as for the first immu-
nostaining. Appropriate controls were carried out and the
specificity of this technique has been reported previously [32].
Semiquantition of Stainings of ChREBP and Glucose
Transporters
Semiquantitative scoring was carried out as described in a
previous study [33]. Briefly, tissue microarray sample ‘spots’
were viewed at 400× magnification and an overall score was
assigned according to intensity and area of positive immuno-
staining. Sample scorings are as follows: 0, no red staining at
all (negative); 1, pink staining in the minority of tissue (mild);
2, pink staining in the majority of the tissue (middle); 3, red
staining in the majority of the tissue (strong) and 4, dark-red
staining in all the tissue (very strong) following a well
established protocol [33]. To reduce the variation of scoring,
all slides, including microarray, were scored by two observers
independently (Y. L. and Q. H.).
Statistical Analysis
The effect of HCC malignancy on protein expression was
analyzed with one-way ANOVA. The correlation between 2
protein expression levels were analyzed with Pearson
Correlation test. If protein expression levels were normally
distributed and had equal variance, Student’s t test was used.
If the scores were not normally distributed, we used theMann-
Whitney U test. p < 0.05 was considered statistically signifi-
cant. All figures and statistics were made with Graphpad
Prism 7 (CA, USA).
Results
Patient Characteristics
A total of 70 liver samples were analyzed, of which 40 were
defined as HCC. Mean age of the 40 cancer patients was
49 years and 82% were males. Stages I, II and III accounted
for 6%, 19% and 33% of total liver samples, respectively. There
were 14 normal liver tissues and 13 cancer adjacent tissues, and
they accounted for 20% and 19%of total, respectively (Table 1).
ChREBP Protein Expression Tended to Increase
with Malignancy
Immunohistochemistry demonstrated that 4 out of 5 pairs of
liver sample clearly showed stronger positive intensity of
ChREBP protein inmalignant tissues than the adjacent normal
tissues (Fig. 1a). Only 1 pair of tissue showed similar intensity
of ChREBP expression in malignant and adjacent normal tis-
sue. The scatter positive signals in non-hepatocytes were T
lymphocytes. All the CD3, T lymphocyte marker, −positive
cells showed positive signals for ChREBP (Fig. S1A-B).Most
of the CD68, macrophage marker, −positive cells did not
show clear ChREBP signals, but a few cells showed mild
positive signals (Fig. S1C-D).
ChREBP immunohistochemistry was also performed in
tissues of different HCC clinical stages to determine whether
there is an association between ChREBP expression and ma-
lignancy. The staining results showed a trend of increasing
intensity of ChREBP with HCC malignant progression as de-
fined by histopathological diagnosis (Fig. 1b). The staining
positivity was quantified with a score defined by staining in-
tensity and size of positive area (Table 2). In normal and HCC
adjacent tissues, about 40% of the sections showed no
ChREBP positivity and about 37% showed mild ChREBP
positivity, but no sections showed strong or very strong
stainings. However, in stage II and stage III HCC tissues,
about 30% of the sections showed no ChREBP expression,
Table 1 Patient information
Total samples 70
Average age of cancer patient (mean ± SD) 49 ± 10
Number Percentage (%)
Male with cancer 33 82%
Female with cancer 7 18%
Normal tissue 14 20%
Adjacent normal tissue 13 19%
Stage I 4 6%
Stage II 13 19%
Stage III 23 33%
Fatty degeneration 3 4%
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25% showed mild staining, 9% showed strong expression,
and 16% showed very strong positivity (Table 2). The strong
and very strong stainings were only seen in highly malignant
(Stages II and III) HCC tissues (Fig. 4a and Table 2).
However, the result of one-way ANOVA of ChREBP expres-
sion and clinical stage found no significant difference (p =
0.172). Therefore, there was only a tendency of increased
ChREBP expression with malignancy.
GLUT2 Protein Expression Negatively Correlates
to Malignancy
Since it has been reported that glycolysis is increased in various
cancer cells [34, 35] and GLUT2 is the main glucose transporter
in liver [18], GLUT2 protein expression was examined (Fig. 2).
In HCC, no GLUT2 protein expression was detected (Fig. 2A,
a), while GLUT2 was highly expressed in the adjacent normal
liver tissue, mainly at the hepatocyte membrane (Fig. 2A, b). In
addition, GLUT2 expressionwas decreased withmalignant pro-
gression (Fig. 2B and Fig. 4b). In normal hepatocytes, GLUT2
protein was clearly detectable at the hepatocyte membrane (Fig.
2B, a). In stage I liver cancer tissues, no positive signal could be
detected (Fig. 2B, b). In stage II, most of the samples showed
mild positivity (Fig. 2B, c), but in stage III most tissues showed
no signal (Fig. 2B, d). Quantification of stain positivity was
carried out based on the positivity scores that were defined by
staining intensity and size of positive area (Table 2 and Fig. 4b).
It showed that in normal tissue about 36% showed medium
GLUT2 positivity, 40% showed strong or very strong staining.
Only a few normal liver tissue sections showed negative or mild
staining. In stage I HCC, 100% of the sections showed no stain-
ing. This may be attributed to limited number of samples in
Stage I. In stage II HCC, about 77% of the sections showed
negative or mild GLUT2 staining. In stage III HCC, about 90%
of the sections showed negative or mild GLUT2 staining (Fig.
4b). The result of one-way ANOVA of GLUT2 protein expres-
sion and clinical stage revealed that GLUT2 protein expression
negatively correlates to liver malignancy (P < 0.001) (Fig. 4b).
GLUT1 Protein Expression Positively Correlates
to Liver Malignancy
Since it has been reported that GLUT1 expression might in-
crease to contribute to increased glycolysis in some cancers
Fig. 1 ChREBP immunohistochemistry in HCC and normal liver
tissue. A The strong ChREBP positive staining in malignant liver (a)
compared with mild staining in adjacent normal tissue (b) in a same
patient. Scale bar = 30 μm. B ChREBP staining in liver cancer tissues
with different malignant progression. a, normal liver tissue; b, stage I liver
cancer; c, stage II liver cancer; d, stage III liver cancer. Scale bar = 30 μm
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Fig. 2 GLUT2 immunohistochemistry in HCC and normal liver
tissue. A The GLUT2 staining was negative in liver cancer (a) but
positive on the membrane of the adjacent normal hepatocytes (b). B
GLUT2 staining in liver cancer tissues with different malignant
progression. a, normal liver tissue; b, stage I liver cancer; c, stage II liver
cancer; d, stage III liver cancer. Scale bar = 30 μm
Table 2 Expression of ChREBP,
GLUT2 and GLUT1 in different
clinical stages












Normal 36% 36% 28% 0% 0%
Adjacent 46% 39% 15% 0% 0%
I 50% 25% 25% 0% 0%
II 31% 23% 23% 8% 15%
III 30% 26% 17% 9% 18%
GLUT2 expression in different clinical stages
Normal 7% 14% 36% 21% 22%
Adjacent 15% 15% 39% 31% 0%
I 100% 0% 0% 0% 0%
II 54% 23% 15% 8% 0%
III 61% 26% 9% 4% 0%
GLUT1 expression in different clinical stages
Normal 64% 36% 0% 0% 0%
Adjacent 69% 23% 8% 0% 0%
I 25% 50% 25% 0% 0%
II 8% 31% 23% 38% 0%
III 9% 26% 35% 26% 4%
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[36], we examined GLUT1 expressions on the liver tissues.
We found that GLUT1 expression in HCC was significantly
higher than that of the adjacent normal tissue (Fig. 3a). The
non-hepatocyte positive cells were red blood cells because of
the lacking of nuclei (Fig. S2). Besides, GLUT1 expression
was increased with malignant progression (Fig. 3b and Fig.
4c). In normal hepatocytes, no GLUT1 positive signal
could be detected (Fig. 3B, a). In stage I liver cancer
tissues, only weak positive signals were detected (Fig.
3B, b). In stage II, most of the samples showed mild
positivity (Fig. 3B, c), and in stage III, most hepatocytes
showed strong positive signals on cell membrane and in
Fig. 3 GLUT1 immunohistochemistry in HCC and normal liver
tissue. A The GLUT1 staining was positive on the membrane and in
the cytoplasm in malignant hepatocytes (a) but negative in the adjacent
normal hepatocytes (b). B GLUT1 staining in liver cancer tissues with
different malignant progression. a, normal liver tissue; b, stage I liver
cancer; c, stage II liver cancer; d, stage III liver cancer. Scale bar = 30 μm
Fig. 4 Histograms of protein expression in different liver tissues.
Histograms of scores of ChREBP (a), GLUT2 (b), GLUT1(c)
expression levels in different stages of liver cancer. 0, absent of positive
signal; 1, mild staining; 2, middle staining; 3, strong staining; 4, very
strong staining. One-way ANOVA was used to analyze the correlation
between protein expression and liver malignancy. Student-T test or
Mann-Whitney U test was used to analyze the protein expression differ-
ences between 2 different clinical stages. **, P < 0.01; ***, P < 0.001
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cytoplasm (Fig. 3B, d). Quantification of the staining in-
tensity (Table 2) showed that in normal tissues, only 36%
showed mild positivity and majority (64%) of the sections
showed no GLUT1 staining. In HCC adjacent tissues,
similar expression pattern was observed to that in the
normal tissues. In stage I HCC, 25% of the sections
showed negative staining, while mild positivity represent-
ed 50% and medium positivity 25%. No strong or very
strong positivity was observed in stage I HCC. In stage
II HCC, however, 8% of the sections showed GLUT1
negative expression, 31% showed mild positivity, 23%
showed medium positivity and 38% showed strong pos-
itivity. In stage III HCC, 9% of the sections showed
GLUT1 negative expression, 26% showed mild positiv-
ity, 35% showed medium positivity and 30% showed
strong and very strong positivity (26% strong, 4% very
strong) (Fig. 4c). The result of one-way ANOVA of
GLUT1 expression and clinical stage showed that GLUT1
protein expression was increased significantly (P < 0.001) fol-
lowing malignant progression of HCC (Fig.4c).
Correlations between Different Protein Expression
Levels
To study the relationships among expressions of ChREBP,
GLUT1 and GLUT2, the Pearson Correlation test was per-
formed between any two different proteins. Although
ChREBP had the trend to increase and GLUT2 expression
decreased with HCCmalignant progression, there was no cor-
relation between these 2 proteins (r = −0.031, p = 0.796, n =
70). However, GLUT1 expression was significantly positively
correlated with ChREBP expression, and both proteins in-
creased with HCC malignancy (r = 0.481, p < 0.0001, n =
70). GLUT1 expression was inversely associated with
GLUT2 expression (r = −0.320, p = 0.007, n = 70).
GLUT1 but Not GLUT2 Protein Co-Expressed
with ChREBP in HCC
To further investigate ChREBP, GLUT2 and GLUT1 protein
expression patterns, stain-decolorize-stain method was
Fig. 5 GLUT1 but not GLUT2 protein co-expressed in ChREBP-
positive hepatocytes in HCC. Immunohistochemistry of ChREBP-
positive malignant hepatocytes (a) showing GLUT2 negative (c) but
GLUT1 positive (e) staining. Arrow heads indicating the same cell.
Immunohistochemistry of ChREBP-negative malignant hepatocytes (b)
showing GLUT2 positive on the membrane (d) but GLUT1 negative
staining (f). Arrow indicating the same cell. Scale bar = 30 μm
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performed. The results showed that GLUT1 but not GLUT2
positive staining could be detected in ChREBP-positive hepa-
tocytes (Fig. 5a c and e). However strong GLUT2 but not
GLUT1 positive staining was detected in ChREBP-negative
hepatocytes (Fig. 5b, d and f). All slides showed that ChREBP
and GLUT1 but not GLUT2 co-expressed in the same cells.
Discussion
It has been proposed that the glucose-sensitive transcription
factor ChREBP plays a role in cancer pathology. It has been
reported that suppression of ChREBP mRNA inhibited cell
proliferation in vitro and reduced tumor growth in vivo [29].
ChREBP protein expression was positively correlated to
breast cancer malignancy, i.e., more malignant cancers ex-
press more ChREBP protein [30]. However, in hepatocellular
carcinoma, the relationship between ChREBP expression and
cancer malignancy has not been established. In this study, we
found that ChREBP protein expression tended to increase
with cancer progression although, with the limited number
of samples, could not reach statistical significance in compas-
sion to normal liver tissue. In normal liver tissue, there was no
or weak ChREBP protein expression, but in liver cancers the
expression was abundant. In stage III HCC patients, 32% of
the samples showed strong staining of ChREBP. The in-
creased ChREBP expression may serve to support increased
glycolysis and lipogenesis in cancerous hepatocytes.
Although ChREBP protein levels can be used as a novel di-
agnostic and prognostic marker in breast cancer [30], variation
in HCC appears to be too large for this purpose. Nevertheless,
ChREBP may contribute to diagnosis of cancer grading in
combination with other markers.
Most cancer cells have increased aerobic glycolysis under
both anaerobic and aerobic conditions [37]. This increased gly-
colysis, accompanied by accelerated glucose uptake, is known
as the Warburg effect, after the German biochemist Otto
Warburg who first described the phenomenon in 1920s [38].
Increased glucose uptake is contributed by transmembrane
transport mediated by specific glucose transporters [39, 40]
and increased activity of hexokinases [41, 42]. Many studies
have demonstrated that the expression of glucose transporters,
especially GLUT1, was increased in a variety of malignancies
and GLUT1 overexpression was associated with invasiveness
and poor overall survival of various malignant tumors [43–47].
GLUT2mRNA expression was inversely associated with over-
all survival in HCC [18] and invasiveness in insulinomas [20].
Thus our data confirm that GLUT2 can be potentially used for
HCC diagnosis and prognostic prediction [18]. It has been re-
ported that GLUT2 is a target of ChREBP [22], but its expres-
sion had an opposite pattern compared to ChREBP in our study.
The possible reason could be that GLUT2 is not only regulated
by ChREBP but also that other regulators could have stronger
influences on GLUT2 expression. This notion, however, re-
quires further investigation.
It has been reported that the increased glucose transport
was due, at least in part, to increased expression of GLUT1
in cancers compared to normal tissues [36] and that GLUT2
was replaced by GLUT1 in human hepatocellular carcinoma
cell line HepG2 [48]. These results suggest that the increased
expression of GLUT1 gene may closely relate to cellular
transformation. In our study, we found that GLUT1 was sig-
nificantly increased in HCC compared to adjacent normal he-
patocytes and its expression was positively associated with
HCC progression. Therefore, GLUT1 might serve as a diag-
nostic marker for HCC. Moreover, we found that ChREBP-
expressing hepatocytes do not express GLUT2 protein but
express GLUT1, and that ChREBP-negative hepatocytes ex-
press GLUT2 but not GLUT1. This indicates that ChREBP
and GLUT1 have a similar expression profile. Upon statistical
analysis, we found that ChREBP and GLUT1 protein levels
were significantly positively correlated to each other and
GLUT1 and GLUT2 levels were significantly reversely asso-
ciated. Different glucose transporters have different binding
affinities for glucose. GLUT1/HKIV has high affinity for glu-
cose [46] but GLUT2/GCK has relatively low affinity for
glucose, mannose and galactose [47]. Therefore, a transition
from GLUT2/GCK to GLUT1/HKIV mediated glucose me-
tabolism could contribute to cancer differentiation because of
losing sensitivity of the liver to circulating glucose levels.
Taken together, this is to our best knowledge the first to
report of ChREBP expression in HCC and its relationship
with glucose transporters GLUT1 and GLUT2. Analysis of
combined profile of ChREBP, GLUT1 and GLUT2 expres-
sion should be helpful for HCC diagnosis and shed light on
improvement of HCC treatment and patient survival.
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